These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 28167231)

  • 1. Nicotine slows down oligomerisation of α-synuclein and ameliorates cytotoxicity in a yeast model of Parkinson's disease.
    Kardani J; Sethi R; Roy I
    Biochim Biophys Acta Mol Basis Dis; 2017 Jun; 1863(6):1454-1463. PubMed ID: 28167231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Smoking and Parkinson's disease: does nicotine affect alpha-synuclein fibrillation?
    Hong DP; Fink AL; Uversky VN
    Biochim Biophys Acta; 2009 Feb; 1794(2):282-90. PubMed ID: 19013262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural Features and Toxicity of α-Synuclein Oligomers Grown in the Presence of DOPAC.
    Palazzi L; Fongaro B; Leri M; Acquasaliente L; Stefani M; Bucciantini M; Polverino de Laureto P
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34199427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accelerated formation of alpha-synuclein oligomers by concerted action of the 20S proteasome and familial Parkinson mutations.
    Lewis KA; Yaeger A; DeMartino GN; Thomas PJ
    J Bioenerg Biomembr; 2010 Feb; 42(1):85-95. PubMed ID: 20148295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential inhibition of α-synuclein oligomeric and fibrillar assembly in parkinson's disease model by cinnamon extract.
    Shaltiel-Karyo R; Davidi D; Frenkel-Pinter M; Ovadia M; Segal D; Gazit E
    Biochim Biophys Acta; 2012 Oct; 1820(10):1628-35. PubMed ID: 22575665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding Caffeine's Role in Attenuating the Toxicity of α-Synuclein Aggregates: Implications for Risk of Parkinson's Disease.
    Kardani J; Roy I
    ACS Chem Neurosci; 2015 Sep; 6(9):1613-25. PubMed ID: 26167732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Α-synuclein misfolding and Parkinson's disease.
    Breydo L; Wu JW; Uversky VN
    Biochim Biophys Acta; 2012 Feb; 1822(2):261-85. PubMed ID: 22024360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of sheep α-synuclein provides a molecular strategy for the reduction of fibrillation.
    Bickle L; Hopwood JJ; Karageorgos L
    Biochim Biophys Acta Proteins Proteom; 2017 Mar; 1865(3):261-273. PubMed ID: 28007442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gelsolin co-occurs with Lewy bodies in vivo and accelerates α-synuclein aggregation in vitro.
    Welander H; Bontha SV; Näsström T; Karlsson M; Nikolajeff F; Danzer K; Kostka M; Kalimo H; Lannfelt L; Ingelsson M; Bergström J
    Biochem Biophys Res Commun; 2011 Aug; 412(1):32-8. PubMed ID: 21798243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formation of dopamine-mediated alpha-synuclein-soluble oligomers requires methionine oxidation.
    Leong SL; Pham CL; Galatis D; Fodero-Tavoletti MT; Perez K; Hill AF; Masters CL; Ali FE; Barnham KJ; Cappai R
    Free Radic Biol Med; 2009 May; 46(10):1328-37. PubMed ID: 19248830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aggregate clearance of α-synuclein in Saccharomyces cerevisiae depends more on autophagosome and vacuole function than on the proteasome.
    Petroi D; Popova B; Taheri-Talesh N; Irniger S; Shahpasandzadeh H; Zweckstetter M; Outeiro TF; Braus GH
    J Biol Chem; 2012 Aug; 287(33):27567-79. PubMed ID: 22722939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting alpha-synuclein for the treatment of Parkinson's disease.
    Rohn TT
    CNS Neurol Disord Drug Targets; 2012 Mar; 11(2):174-9. PubMed ID: 22483285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological roles of α-synuclein in neurological disorders.
    Vekrellis K; Xilouri M; Emmanouilidou E; Rideout HJ; Stefanis L
    Lancet Neurol; 2011 Nov; 10(11):1015-25. PubMed ID: 22014436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions of α-synuclein oligomers with lipid membranes.
    Musteikytė G; Jayaram AK; Xu CK; Vendruscolo M; Krainer G; Knowles TPJ
    Biochim Biophys Acta Biomembr; 2021 Apr; 1863(4):183536. PubMed ID: 33373595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of protein interfaces between α-synuclein, the principal component of Lewy bodies in Parkinson disease, and the molecular chaperones human Hsc70 and the yeast Ssa1p.
    Redeker V; Pemberton S; Bienvenut W; Bousset L; Melki R
    J Biol Chem; 2012 Sep; 287(39):32630-9. PubMed ID: 22843682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
    Lee VM; Trojanowski JQ
    Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experimental animal models of Parkinson's disease: A transition from assessing symptomatology to α-synuclein targeted disease modification.
    Ko WKD; Bezard E
    Exp Neurol; 2017 Dec; 298(Pt B):172-179. PubMed ID: 28764902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-Terminal Tyrosine Residue Modifications Modulate the Protective Phosphorylation of Serine 129 of α-Synuclein in a Yeast Model of Parkinson's Disease.
    Kleinknecht A; Popova B; Lázaro DF; Pinho R; Valerius O; Outeiro TF; Braus GH
    PLoS Genet; 2016 Jun; 12(6):e1006098. PubMed ID: 27341336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Membrane interactions of oligomeric alpha-synuclein: potential role in Parkinson's disease.
    van Rooijen BD; Claessens MM; Subramaniam V
    Curr Protein Pept Sci; 2010 Aug; 11(5):334-42. PubMed ID: 20423294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.